Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 76.03M shares outstanding
TWJyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases.
The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
Fenglin Hsu
Chief Technology Officer & Director
Fu-Feng Kuo
Chief Executive Officer & Chairwoman of the Board
Wanwen Su
Chief Science Officer
Wei Zhang
Chief Financial Officer
Employees
31
Country
TW
Sector
Healthcare
Website
jyongbio.com
Loading congressional disclosures…
based on 76.03M shares outstanding
TW30d Avg
45.96K
60d Avg
40.84K
90d Avg
44.78K
